# A Study to Evaluate HB0034 in Healthy Adult Participants

> **NCT05064345** · PHASE1 · COMPLETED · sponsor: **Shanghai Huaota Biopharmaceutical Co., Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HB0034
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05064345
- **Lead sponsor:** Shanghai Huaota Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-03
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2022-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05064345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05064345, "A Study to Evaluate HB0034 in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05064345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*